Ind-Swift Laboratories Limited Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited

INDSWFTLAB

Rank in Stocks #14199
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the... Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Share Price
$3.85
Last synced: 2026-11-12
Market Cap
$334.46M
Change (1 day)
-0.53%
Change (1 year)
252.58%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Ind-Swift Laboratories Limited (INDSWFTLAB)

Category

Healthcare
EPS for Ind-Swift Laboratories Limited (INDSWFTLAB)
EPS as of September 2026 TTM: $0.10
According to Ind-Swift Laboratories Limited's latest financial reports, its current EPS (TTM) is $0.10. At the end of 2025 the company had an EPS of $0.44, a decrease compared to its 2024 EPS of $1.09.
EPS history for Ind-Swift Laboratories Limited from 2006 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $0.10 -76.48%
2025 $0.44 -60.17%
2024 $1.09 1,014.68%
2023 $0.10 -2,187.23%
2022 0.00 -34.72%
2021 $-0.01 -87.32%
2020 $-0.06 -156.02%
2019 $0.10 35.92%
2018 $0.07 -152.57%
2017 $-0.14 -34.40%
2016 $-0.22 -53.68%
2015 $-0.47 -6.04%
2014 $-0.50 -10.26%
2013 $-0.55 -212.95%
2012 $0.49 -26.58%
2011 $0.67 43.77%
2010 $0.46 45.38%
2009 $0.32 -6.19%
2008 $0.34 79.83%
2007 $0.19 -50.00%
2006 $0.38 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 5,725.99%
DE
$6.01 5,704.64%
DE
$1.53 1,381.06%
JP
$3.66 3,436.23%
CH
$0.45 334.78%
IL

Questions about Ind-Swift Laboratories Limited's earnings per share (EPS)

What is Ind-Swift Laboratories Limited's earnings per share (EPS)?

Ind-Swift Laboratories Limited's earnings per share (EPS) over the last twelve months is $0.10, as of Sep 2026.

What was Ind-Swift Laboratories Limited's earnings per share (EPS) in 2025?

In 2025, Ind-Swift Laboratories Limited's earnings per share (EPS) was $0.44, 59.63% less than in 2024 ($1.09).

How has Ind-Swift Laboratories Limited's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Ind-Swift Laboratories Limited's earnings per share (EPS) was highest in 2024 ($1.09) and lowest in 2020 ($-0.06).

How does Ind-Swift Laboratories Limited's earnings per share (EPS) compare with similar companies?

Ind-Swift Laboratories Limited's earnings per share (EPS) ($0.10) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.